 Shares of CureVac CVAC, -1.37 tumbled 9.6 in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline GSK, -1.21 . The existing purchase agreement with the European Commission is no longer in place. 